Sept. 13, 2002 — Altair Nanotechnologies Inc. said it has named its new drug for the removal of phosphate ions in kidney dialysis patients.
Renazorb has been developed specifically to treat elevated phosphate levels in patients with end-stage renal disease. The drug is a ceramic microstructured material that binds phosphate and is designed to remove ions in the gastrointestinal tract without absorption of the drug into the bloodstream, according to a news release.
Altair said it has signed four agreements with pharmaceutical firms. Three of them are interested in using Renazorb in a filtration device that could be used during dialysis to remove phosphate directly from the blood serum, the release said.